Skip to main navigation

Skip to content

Side Menu

About Us
Our Platform
Our Programs
Patients and Physicians
Inside Seres
Investors and News
Contact Us

Press Releases

Seres' news, events and other information can be found throughout the pages below.

Investor Relations

Stock Information
News and Events
- Press Releases
- Events & Presentations
Financial Information
- SEC Filings
- Annual Reports
Corporate Governance
Shareholder Services

Press Releases

Keyword Search

Year

Nov 19, 2020

Seres Therapeutics to Participate in Upcoming Virtual Investor Conferences

Nov 09, 2020

Seres Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Updates

Nov 06, 2020

Seres Therapeutics Announces Initiation of Phase 1b Trial of SER-301 for the Treatment of Ulcerative Colitis

Nov 02, 2020

Seres Therapeutics to Host Third Quarter 2020 Financial Results and Operational Progress Conference Call and Webcast on November 9, 2020

Oct 22, 2020

Seres Therapeutics Expands Executive Team with Appointments of David S. Ege, Ph.D., as Chief Technology Officer and Jayne M. Gansler as Chief People Officer

Oct 12, 2020

Seres Therapeutics to Present SER-109 Phase 3 ECOSPOR III Study Results at American College of Gastroenterology Annual Scientific Meeting

Sep 22, 2020

Seres Therapeutics to Present at the Jefferies Next Generation IBD Therapeutics Summit

Sep 14, 2020

Seres Therapeutics to Present at Upcoming Investor Conferences

Sep 11, 2020

Seres Therapeutics Announces U.S. Food and Drug Administration Correspondence Following Positive SER-109 Phase 3 Study Results

Aug 17, 2020

Seres Therapeutics, Inc. Announces Closing of Public Offerings of 12,075,000 Shares of Common Stock

Pagination

Current page 1
Page 2
Page 3
Next page
Last page

Shareholder Tools

RSS Feeds
E-mail Alerts
Print

© 2020 Seres Therapeutics.

Footer Left Menu

Privacy Policy
Terms of Use

Follow us on Linkedin
Follow us on Twitter
Follow us on Facebook